EQS-Adhoc: aap Implantate AG: resolves to convene an Annual General Meeting to elect a new auditor
|
EQS-Ad-hoc: aap Implantate AG / Key word(s): AGM/EGM The Management Board of aap Implantate AG (the "Company") today resolved to convene a General Meeting to resolve on the proposal of the Supervisory Board on the appointment of a new auditor for the financial year 2024. The background to the Supervisory Board's proposal is that the auditor elected by the Annual General Meeting on August 15, 2024 for the financial year 2024 informed the Company today that he will not be available for the audit of the annual and consolidated financial statements of the Company for the financial year 2024 and therefore no mandate relationship for the audit of the annual and consolidated financial statements for the financial year 2024 will be established between the Company and the auditor elected by the Annual General Meeting. The company assumes that the Audit Committee will nominate a new auditor at its meeting on Thursday, December 5, 2024, after completion of the ongoing simplified selection procedure in accordance with Art. 16 EU Regulation 537/2014, which the Supervisory Board will propose to the company's shareholders for election at the Annual General Meeting, which is scheduled to take place on January 15, 2025. This Annual General Meeting will also deal with other agenda items not discussed at the Annual General Meeting on August 15, 2024.
---------------------------------------------------------------- aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock exchanges - About aap Implantate AG aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. In addition to the innovative LOQTEQ® anatomical plate system, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. Sales are conducted both through distribution agents and through partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.
Forward-looking statements This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.
If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Management Board/ CEO; Lorenzweg 5; 12099 Berlin Phone: +49 (0)30 75019 - 141; Fax: +49 (0)30 75019 - 290; Email: r.digirolamo@aap.de End of Inside Information
03-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | aap Implantate AG |
| Lorenzweg 5 | |
| 12099 Berlin | |
| Germany | |
| Phone: | +49 (0) 30 75 019-0 |
| Fax: | +49 (0) 30 75 019-111 |
| E-mail: | info@aap.de |
| Internet: | www.aap.de |
| ISIN: | DE000A3H2101 |
| WKN: | A3H210 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2043555 |
| End of Announcement | EQS News Service |
|
|
2043555 03-Dec-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 10,78 | 11,74 | 9,33 | 12,17 | 11,52 | 11,48 | 12,20 | |
| EBITDA1,2 | -6,41 | -5,14 | -4,77 | -0,77 | -1,71 | -3,67 | 0,16 | |
| EBITDA-Margin3 | -59,46 | -43,78 | -51,13 | -6,33 | -14,84 | -31,97 | 1,31 | |
| EBIT1,4 | -8,13 | -19,77 | -7,89 | -2,61 | -3,39 | -5,19 | -1,60 | |
| EBIT-Margin5 | -75,42 | -168,40 | -84,57 | -21,45 | -29,43 | -45,21 | -13,12 | |
| Net Profit (Loss)1 | -7,67 | -19,52 | -8,79 | -2,52 | -2,56 | -5,13 | -1,85 | |
| Net-Margin6 | -71,15 | -166,27 | -94,21 | -20,71 | -22,22 | -44,69 | -15,16 | |
| Cashflow1,7 | -5,92 | -5,77 | -3,68 | -2,47 | -1,89 | -2,99 | 0,00 | |
| Earnings per share8 | -2,70 | -6,10 | -2,79 | -0,51 | -0,39 | -0,58 | -0,17 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| aap Implantate | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3H210 | DE000A3H2101 | AG | 15,59 Mio € | 10.05.1999 | 9F4MF94Q+7M | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 0,00 | 0,00 | 0,00 | -0,77 | 1,44 | -5,21 | 1,36 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.01.2025 | - | 14.08.2024 | - | 23.08.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -24,71% | +5,89% | +71,08% | +83,23% | -98,58% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
